West Pharmaceutical Svsc (WST) Holder Nj State Employees Deferred Compensation Plan Has Decreased Stake by $1.88 Million; As Orbcomm (ORBC) Stock Rose, Holder Levy Harkins & Company Has Cut by $714,846 Its Stake

December 16, 2017 - By Louis Casey

Nj State Employees Deferred Compensation Plan decreased its stake in West Pharmaceutical Svsc Inc (WST) by 66.67% based on its latest 2017Q2 regulatory filing with the SEC. Nj State Employees Deferred Compensation Plan sold 20,000 shares as the company’s stock rose 14.65% with the market. The institutional investor held 10,000 shares of the basic industries company at the end of 2017Q2, valued at $945,000, down from 30,000 at the end of the previous reported quarter. Nj State Employees Deferred Compensation Plan who had been investing in West Pharmaceutical Svsc Inc for a number of months, seems to be less bullish one the $7.33B market cap company. The stock increased 0.50% or $0.49 during the last trading session, reaching $98.73. About 653,817 shares traded or 80.56% up from the average. West Pharmaceutical Services, Inc. (NYSE:WST) has risen 33.75% since December 16, 2016 and is uptrending. It has outperformed by 17.05% the S&P500.

Levy Harkins & Company Inc decreased its stake in Orbcomm Inc. (ORBC) by 2.32% based on its latest 2017Q2 regulatory filing with the SEC. Levy Harkins & Company Inc sold 64,986 shares as the company’s stock rose 16.75% with the market. The hedge fund held 2.74 million shares of the telecommunications equipment company at the end of 2017Q2, valued at $30.94M, down from 2.80M at the end of the previous reported quarter. Levy Harkins & Company Inc who had been investing in Orbcomm Inc. for a number of months, seems to be less bullish one the $731.79 million market cap company. The stock decreased 0.61% or $0.06 during the last trading session, reaching $9.85. About 314,281 shares traded. ORBCOMM Inc. (NASDAQ:ORBC) has risen 5.18% since December 16, 2016 and is uptrending. It has underperformed by 11.52% the S&P500.

Among 5 analysts covering West Pharmaceutical Services (NYSE:WST), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. West Pharmaceutical Services had 13 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Wells Fargo to “Outperform” on Friday, October 28. Jefferies maintained the shares of WST in report on Thursday, July 27 with “Hold” rating. The firm earned “Hold” rating on Tuesday, June 6 by Jefferies. Jefferies maintained it with “Hold” rating and $10000 target in Thursday, June 29 report. Wells Fargo downgraded the stock to “Market Perform” rating in Wednesday, September 21 report. The firm earned “Outperform” rating on Tuesday, March 22 by Wells Fargo. Jefferies upgraded the shares of WST in report on Friday, September 15 to “Buy” rating. The rating was downgraded by Zacks to “Hold” on Tuesday, August 4. Bank of America downgraded West Pharmaceutical Services, Inc. (NYSE:WST) on Tuesday, October 17 to “Hold” rating. Jefferies maintained West Pharmaceutical Services, Inc. (NYSE:WST) on Monday, September 11 with “Hold” rating.

Since December 8, 2017, it had 0 insider buys, and 1 insider sale for $2.08 million activity.

Nj State Employees Deferred Compensation Plan, which manages about $529.76 million US Long portfolio, upped its stake in Five Below Inc (NASDAQ:FIVE) by 10,000 shares to 18,000 shares, valued at $889,000 in 2017Q2, according to the filing. It also increased its holding in Eros Intl Plc (NYSE:EROS) by 40,000 shares in the quarter, for a total of 80,000 shares, and has risen its stake in Atlas Air Worldwide Hldgs In.

Analysts await West Pharmaceutical Services, Inc. (NYSE:WST) to report earnings on February, 15. They expect $0.61 EPS, up 12.96% or $0.07 from last year’s $0.54 per share. WST’s profit will be $45.29M for 40.46 P/E if the $0.61 EPS becomes a reality. After $0.67 actual EPS reported by West Pharmaceutical Services, Inc. for the previous quarter, Wall Street now forecasts -8.96% negative EPS growth.

Investors sentiment increased to 1.61 in Q2 2017. Its up 0.35, from 1.26 in 2017Q1. It increased, as 23 investors sold WST shares while 76 reduced holdings. 44 funds opened positions while 115 raised stakes. 67.09 million shares or 1.84% more from 65.87 million shares in 2017Q1 were reported. Dorsey Wright & Associate owns 28,139 shares. Gemmer Asset Mngmt Limited Co invested in 0.01% or 169 shares. Texas Permanent School Fund stated it has 53,702 shares. Cibc Ww Mkts accumulated 2,956 shares. 1832 Asset Management Lp has 0.12% invested in West Pharmaceutical Services, Inc. (NYSE:WST). Copper Rock Partners Limited Liability Corporation reported 338,083 shares stake. Amp Cap Invsts Ltd reported 0.01% stake. 384,533 were reported by Morgan Stanley. Sterling Capital Mgmt stated it has 327,300 shares. Capstone Investment Advsrs Ltd Limited Liability Company owns 21,760 shares. Paloma Partners Mgmt Co reported 13,572 shares. Regions Fincl Corp reported 4,084 shares stake. Pub Employees Retirement Association Of Colorado owns 230,195 shares for 0.16% of their portfolio. Moreover, Kistler has 3.15% invested in West Pharmaceutical Services, Inc. (NYSE:WST) for 72,708 shares. Kings Point Capital Management holds 13,272 shares.

Among 4 analysts covering ORBCOMM (NASDAQ:ORBC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ORBCOMM had 15 analyst reports since March 14, 2016 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, November 28. The stock of ORBCOMM Inc. (NASDAQ:ORBC) has “Outperform” rating given on Monday, October 31 by Macquarie Research. The firm has “Buy” rating given on Thursday, November 2 by Canaccord Genuity. Northland Capital maintained it with “Buy” rating and $13.0 target in Monday, August 28 report. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, July 12. The firm earned “Buy” rating on Friday, September 29 by Northland Capital. Northland Capital maintained the shares of ORBC in report on Monday, March 14 with “Outperform” rating. Canaccord Genuity maintained the shares of ORBC in report on Thursday, August 3 with “Buy” rating. The firm earned “Buy” rating on Monday, September 11 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Buy” rating in Friday, May 26 report.

Investors sentiment increased to 1.69 in 2017 Q2. Its up 0.34, from 1.35 in 2017Q1. It improved, as 6 investors sold ORBC shares while 33 reduced holdings. 24 funds opened positions while 42 raised stakes. 54.56 million shares or 0.34% less from 54.75 million shares in 2017Q1 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) reported 2,588 shares stake. Connors Investor Services holds 0.04% or 20,000 shares in its portfolio. Blair William & Il reported 50,804 shares. Wasatch Advsrs invested 0.03% in ORBCOMM Inc. (NASDAQ:ORBC). Magnetar Limited Co owns 15,217 shares or 0% of their US portfolio. Meeder Asset Mngmt has 0% invested in ORBCOMM Inc. (NASDAQ:ORBC) for 595 shares. Washington-based Parametric Associate Ltd Co has invested 0% in ORBCOMM Inc. (NASDAQ:ORBC). Legal & General Group Public Limited has invested 0% in ORBCOMM Inc. (NASDAQ:ORBC). 116,061 are held by California State Teachers Retirement System. North Star Corp owns 0% invested in ORBCOMM Inc. (NASDAQ:ORBC) for 3,000 shares. Royal Savings Bank Of Canada invested in 168 shares or 0% of the stock. Ariel Invests Limited Co holds 2.16 million shares. 621,903 are held by Cortina Asset Mgmt Limited Co. Bankshares Of Nova Scotia has 0% invested in ORBCOMM Inc. (NASDAQ:ORBC). Vestor Cap Ltd Liability Co holds 0.01% or 3,925 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: